Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Inc. - Common Stock (NQ:TVGN)

6.280 +0.030 (+0.48%)
Delayed Quote Updated: 3:42 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tevogen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? ↗
Tevogen Bio Holdings shares are ripping higher in Monday's after-hours session after the company reaffirmed its oncology pipeline revenue forecast. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces 2025 Annual Meeting
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential ↗
D Boral Capital initiates Buy on Tevogen Bio citing its scalable T-cell therapies and upcoming clinical readouts, with a $10 price target. 
Via Benzinga
News headline image
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
News headline image
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
From Tevogen Bio Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.